Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm - PubMed
19 hours ago
- #KRAS
- #Pancreatic Cancer
- #Targeted Therapy
- Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with limited effective treatments.
- KRAS mutations occur in over 90% of PDAC cases and drive tumor growth, resistance, and immune evasion.
- New allele-specific inhibitors and pan-RAS(ON) agents now make KRAS a viable therapeutic target, showing antitumor activity in early trials.
- Combination therapies, including with chemotherapy, immunotherapy, and novel approaches like KRAS degradation, are being explored to enhance response durability.
- Advances in targeting KRAS signal a shift towards precision medicine in PDAC, offering hope for improved outcomes.